Charles River Laboratories International, Inc. $CRL Shares Newly Acquired by Apollon Wealth Management LLC

Key Points

• Apollon Wealth Management acquired 5,019 shares of Charles River Laboratories, valued at approximately $1.48 million. Institutional investors collectively own 98.91% of the company.
• Analyst sentiment is generally positive, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $302.33; price targets range from $219 to $357.
• Charles River exceeded quarterly earnings expectations, reporting $3.02 in EPS versus the $2.77 consensus and $1 billion in revenue, although revenue declined 2.7% year over year. Insiders sold 118,169 shares worth $35.2 million during the quarter.

Apollon Wealth Management LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,019 shares of the medical research company's stock, valued at approximately $1,481,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in shares of Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock valued at $285,001,000 after buying an additional 210,260 shares during the last quarter. Bank of America Corp DE lifted its holdings in Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock valued at $195,792,000 after purchasing an additional 54,500 shares during the last quarter. Amundi lifted its holdings in Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after purchasing an additional 492,301 shares during the last quarter. Van Berkom & Associates Inc. boosted its position in Charles River Laboratories International by 11.2% during the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company's stock worth $86,449,000 after purchasing an additional 50,462 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in Charles River Laboratories International by 230.9% during the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock worth $59,044,000 after purchasing an additional 142,716 shares during the period. 98.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CRL shares. Barclays upped their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, September 25th. Mizuho raised their target price on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a "neutral" rating in a research note on Friday, September 25th. CLSA downgraded shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 target price for the company. in a report on Monday, July 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Charles River Laboratories International in a research note on Monday, September 28th. Finally, UBS Group initiated coverage on shares of Charles River Laboratories International in a report on Wednesday, September 30th. They issued a "buy" rating and a $357.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $302.33.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CAO Michael Knell sold 6,645 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $260.38, for a total value of $1,730,225.10. Following the transaction, the chief accounting officer directly owned 11,852 shares of the company's stock, valued at $3,086,023.76. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Victoria L. Creamer sold 4,179 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company's stock, valued at $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 118,169 shares of company stock worth $35,191,216. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $359.34 on Friday. The stock has a market capitalization of $17.15 billion, a PE ratio of -74.09, a P/E/G ratio of 3.52 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The business has a fifty day moving average price of $302.09 and a two-hundred day moving average price of $222.34. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $379.63.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same period in the prior year, the firm posted $3.12 EPS. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.